ReviewNew microbes and new infections2020
Laboratory diagnosis of SARS-CoV-2: available approaches and limitations.
Review in New microbes and new infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis.International journal of cancer · 2024Pooled it
- Transmission of SARS-CoV-2 among underserved pastoralist communities in Kajiado County, Kenya: 2020-2022.PloS one · 2024Article
- Advancements in SARS-CoV-2 Testing: Enhancing Accessibility through Machine Learning-Enhanced Biosensors.Micromachines · 2023Review
- Emerging trends in point-of-care biosensing strategies for molecular architectures and antibodies of SARS-CoV-2.Biosensors & bioelectronics: X · 2023Review
- Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants.Vaccines · 2023Review
- Analysis of diagnostic performance and factors causing nonspecific reactions in SARS-CoV-2 rapid antigen detection tests.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023Article
- Development and validation of a rapid and easy-to-perform point-of-care lateral flow immunoassay (LFIA) for the detection of SARS-CoV-2 spike protein.Frontiers in immunology · 2023Article
- What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral load evolution and immune response.Frontiers in nephrology · 2023Article
- Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.Frontiers in immunology · 2023Article
- SARS-CoV-2 detection methods: A comprehensive review.Saudi journal of biological sciences · 2022Review
- SEB genotyping: SmartAmp-Eprimer binary code genotyping for complex, highly variable targets applied to HBV.BMC infectious diseases · 2022Article
- SARS-CoV-2 Molecular Diagnostics in China.Clinics in laboratory medicine · 2022Review
- Monoclonal antibody pairs against SARS-CoV-2 for rapid antigen test development.PLoS neglected tropical diseases · 2022Article
- Molecular accuracy vs antigenic speed: SARS-CoV-2 testing strategies.Current opinion in pharmacology · 2022Review
- Viral outbreaks detection and surveillance using wastewater-based epidemiology, viral air sampling, and machine learning techniques: A comprehensive review and outlook.The Science of the total environment · 2022Review
- Adjuvant Therapy System of COVID-19 Patient: Integrating Warning, Therapy, Post-Therapy Psychological Intervention.IEEE transactions on network science and engineering · 2022Article
- Latest Insights on the Diagnostic Approaches and Treatment Strategies of COVID-19.Intervirology · 2022Review
- Article
- Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2.Scientific reports · 2021Article
- Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects.Analytical and bioanalytical chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the most devastating outbreaks witnessed in the last 100 years. The outbreak started in China and spread rapidly to almost every country, culminating in woefully overwhelmed health-care systems in most countries. The only approved diagnostic test to accompany radiographic evaluation is reverse transcription PCR. However, the applicability of this test in diagnosis and surveillance is challenged by a global shortage of reagents and the lack of well-equipped laboratories with specialized staff in several low- and middle-income countries. Loop-mediated isothermal amplification and CRISPR-based diagnostic assays have developed and expected to play a role however, their accuracy is still inferior to the recommended PCR approach. The need for the development of accurate and rapid diagnostic assays became apparent. Immunodiagnostic tests and other molecular approaches were developed and tested. Other recently developed point-of-care molecular tests are expected to be helpful in pandemic management as no particular skills are required from the operator. Fortunately, a number of serological tests have been granted authorization for use under the emergency situation by the US FDA for the diagnosis of SARS-CoV-2. The majority of recently authorized serological tests detect IgG and IgM in blood of infected individuals by on ELISA, chemiluminescence platforms or lateral flow cassettes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.